NeoGenomics Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
2,500
- Stock Symbol
-
NEO
- Investments
-
9
- Share Price
-
$16.01
- (As of Friday Closing)
NeoGenomics General Information
Description
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Contact Information
Website
www.neogenomics.comCorporate Office
- 9490 NeoGenomics Way
- Fort Myers, FL 33912
- United States
Corporate Office
- 9490 NeoGenomics Way
- Fort Myers, FL 33912
- United States
NeoGenomics Stock Performance
As of 13-Nov-2026, NeoGenomics’s stock price is $16.01. Its current market cap is $2.07B with 129M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.01 | $16.54 | $7.07 - $20.15 | $2.07B | 129M | 1.96M | -$0.25 |
NeoGenomics Financials Summary
As of 30-Sep-2026, NeoGenomics has a trailing 12-month revenue of $788M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,661,638 | 1,767,792 | 2,333,842 | 2,265,832 |
| Revenue | 787,752 | 727,332 | 660,566 | 591,643 |
| EBITDA | 27,067 | (47,761) | (19,938) | (34,509) |
| Net Income | (32,295) | (108,025) | (78,726) | (87,968) |
| Total Assets | 1,376,917 | 1,359,830 | 1,638,038 | 1,681,229 |
| Total Debt | 449,141 | 409,456 | 605,334 | 611,679 |
NeoGenomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NeoGenomics Comparisons
Industry
Financing
Details
NeoGenomics Competitors (18)
One of NeoGenomics’s 18 competitors is Quest Diagnostics, a Corporation company based in Secaucus, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quest Diagnostics | Corporation | Secaucus, NJ | ||||
| Gene By Gene | Formerly VC-backed | Houston, TX | ||||
| Interpace Biosciences | Private Debt Financed | Parsippany, NJ | ||||
| PathGroup | Private Equity-Backed | Brentwood, TN | ||||
| Dahl-Chase Diagnostic Services | Private Equity-Backed | Bangor, ME |
NeoGenomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeoGenomics Patents
NeoGenomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202507941-D0 | Methods for detecting minimal residual disease mutational signatures | Pending | 21-May-2025 | ||
| WO-2026220337-A1 | Systems and methods for hybridizing selective enrichment | Pending | 16-Apr-2025 | ||
| WO-2026107240-A1 | Methods and systems for analyzing low-input samples | Pending | 15-Nov-2024 | ||
| EP-4320442-A1 | Perivascular accumulation of immune cells in the diagnosis and treatment of cancer | Pending | 09-Apr-2021 | ||
| US-20240241128-A1 | Perivascular accumulation of immune cells in the diagnosis and treatment of cancer | Pending | 09-Apr-2021 | G01N33/5758 |
NeoGenomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NeoGenomics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
NeoGenomics Investments & Acquisitions (9)
NeoGenomics’s most recent deal was a Merger/Acquisition with Pathline Labs for . The deal was made on 04-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pathline Labs | 04-Apr-2025 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Inivata | 18-Jun-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| Trapelo Health | 07-Apr-2021 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Inivata | 03-Jun-2020 | Later Stage VC | Diagnostic Equipment | ||
| Human Longevity (Oncology Division) | 10-Jan-2020 | Merger/Acquisition | Drug Discovery |
NeoGenomics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
20.7 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
NeoGenomics Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Trapelo Health | Fort Myers, FL | 2009 | |
| Clarient | Aliso Viejo, CA | 1993 | |
| Minuet Diagnostics | Fort Myers, FL |
NeoGenomics FAQs
-
When was NeoGenomics founded?
NeoGenomics was founded in 1999.
-
Where is NeoGenomics headquartered?
NeoGenomics is headquartered in Fort Myers, FL.
-
What is the size of NeoGenomics?
NeoGenomics has 2,500 total employees.
-
What industry is NeoGenomics in?
NeoGenomics’s primary industry is Laboratory Services (Healthcare).
-
Is NeoGenomics a private or public company?
NeoGenomics is a Public company.
-
What is NeoGenomics’s stock symbol?
The ticker symbol for NeoGenomics is NEO.
-
What is the current stock price of NeoGenomics?
As of 13-Nov-2026 the stock price of NeoGenomics is $16.01.
-
What is the current market cap of NeoGenomics?
The current market capitalization of NeoGenomics is $2.07B.
-
What is NeoGenomics’s current revenue?
The trailing twelve month revenue for NeoGenomics is $788M.
-
Who are NeoGenomics’s competitors?
Quest Diagnostics, Gene By Gene, Interpace Biosciences, PathGroup, and Dahl-Chase Diagnostic Services are some of the 18 competitors of NeoGenomics.
-
What is NeoGenomics’s annual earnings per share (EPS)?
NeoGenomics’s EPS for 12 months was -$0.25.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
